Just In
- 1 hr ago Bank Holidays In April 2024: Banks Will Remain Closed For 14 Days, Check Out The Complete List Here!
- 3 hrs ago Aditi Rao Hydari's Double Diamond Engagement Ring Is Unique, Celebrity Wedding Rings That Are Bookmark Worthy!
- 6 hrs ago Navratri 2024 Date In April: When Will Chaitra Navratri Festival Start? Significance Of 9 Days, Deets Inside!
- 7 hrs ago Ramadan 2024: 6 Bollywood-Inspired Outfit Ideas To Shine During The Holy Month
Don't Miss
- Finance 1:10 Stock Split: Small Cap Stock Intimates Record Date, Triple Digit Returns In 180-Days
- Sports RCB vs KKR, IPL 2024: Virat Kohli and Gautam Gambhir Hug It Out, Smile and Talk | Fans React with Love and Surprise
- Movies Elvish Yadav Controversy: Astrologer Janardan Dhurve's Prediction About Bigg Boss OTT 2 Winner Turns Out To Be
- News Delhi Weather Update: IMD Warns Of Heavy Rain, Hailstorms
- Automobiles Citroen Basalt Vs Tata Curvv – The Beauty Contest
- Travel Choosing Your Next Home: Hyderabad Or Pune?
- Education National Management College begins admissions for CA and CMA courses
- Technology Samsung Galaxy M15 5G Launch in India Teased; Could Be Priced Under Rs 15,000
Trial Of New Oral Drug Against COVID-19 Begins In South Africa
Oravax Medical Inc, a subsidiary of US/Israeli pharmaceutical company Oramed, has started the first phase of a clinical trial of its oral COVID-19 vaccine in South Africa.
South Africa has been struggling with its plans to achieve herd immunity through vaccinations, with widespread vaccine hesitancy, largely fuelled by social media misinformation.
There is also a strong anti-vaccination lobby, including some political parties.
"We expect to rapidly complete this study and hope to advance into pivotal trials for emergency use approval in countries where our oral Virus-Like Particles (VLP) vaccine would have the greatest impact," Oramed Chief Executive Officer Nadav Kidron said in a statement.
"South Africa is a great location for the Phase 1 study, as it is currently experiencing a surge in COVID cases and has struggled to obtain sufficient vaccines.
"It is our firm belief that an oral vaccine which eliminates syringes and eases distribution and administration, can significantly help increase vaccination rates for South Africa and similar countries," Kidron said.
The open-label trial involves participants who have not received either a COVID-19 vaccine or contracted the virus. Participants will be administered one dose of the oral vaccine at the beginning of the trial and a second dose three weeks later.
The trial's endpoints will include safety and tolerability as well as efficacy by measuring the presence of an immunogenic response.
Kidron said the trial phase would be short to show as quickly as possible that this oral vaccine works very well on humans before seeking phase two approvals.
Oravax said its oral vaccine targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the COVID-19 virus.
"Oravax's VLP vaccine technology is highly scalable for manufacturing and is easily transferable for logistical wide-scale distribution as there is no need for subfreezing storage," it added.
Oravax Medical Inc. was established earlier this year by Oramed Pharmaceuticals and other shareholders with a mission to bring an oral COVID-19 vaccine to the market.
Specialising in ways to deliver drugs orally, Oramed is currently in an advanced stage of trials for the first commercial oral insulin capsule for the treatment of diabetes.
- disorders cureIndia May See A Covid Surge In January, Next 40 Days Crucial; Here Is How To Protect Yourself From COVID-19
- disorders cureCOVID Can Trigger Parkinson's Disease: Study
- disorders cureCommon COVID Symptoms In Fully Vaccinated Individuals: What You Should Know
- wellnessMild COVID Linked To Life-Threatening Blood Clots, Increased Risk Of Cardiovascular Disease; Study
- wellnessCOVID-19 Variants In India: New COVID Variant May Pose Threat To Elderly People
- basicsCovid-19 Linked To Early Onset Of Periods: What You Need To Know
- wellnessCOVID XBB Variants Of Omicron In India: What You Should Know
- disorders cureNew Omicron Subvariant BQ.1 Detected In Maharashtra: What You Should Know
- disorders cureOmicron BF.7 In India, Risk Of Fresh Wave During Diwali: What You Should Know
- womenPriyanka Chopra Speaks On Climate Change, COVID, Poverty At The UN Sustainable Development Goals 2022 Moment
- wellnessCoronavirus Residues Might Be Causing Long COVID: New Study
- art cultureRenowned Spanish Author Javier Marias Passes Away Due To Lung Infection Post COVID-19